HUP0302665A2 - N-(3-etinilfenil)-6,7-bisz(2-metoxietoxi)-4-kinazolinamin-hidroklorid stabil módosulata, és eljárás előállítására, ezt tartalmazó gyógyszerkészítmények és alkalmazása - Google Patents

N-(3-etinilfenil)-6,7-bisz(2-metoxietoxi)-4-kinazolinamin-hidroklorid stabil módosulata, és eljárás előállítására, ezt tartalmazó gyógyszerkészítmények és alkalmazása

Info

Publication number
HUP0302665A2
HUP0302665A2 HU0302665A HUP0302665A HUP0302665A2 HU P0302665 A2 HUP0302665 A2 HU P0302665A2 HU 0302665 A HU0302665 A HU 0302665A HU P0302665 A HUP0302665 A HU P0302665A HU P0302665 A2 HUP0302665 A2 HU P0302665A2
Authority
HU
Hungary
Prior art keywords
bis
methoxyethoxy
ethynylphenyl
quinazolinamine hydrochloride
ethynylphenylamino
Prior art date
Application number
HU0302665A
Other languages
English (en)
Inventor
Richard D. Connell
Karen J. Ferrante
Barbara A. Foster
Shama M. Kajiji
Michael J. Morin
James D. Moyer
Timothy Norris
Jeffrey W. Raggon
Sandra L. Silberman
Original Assignee
Osi Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27389075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0302665(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osi Pharmaceuticals, Inc. filed Critical Osi Pharmaceuticals, Inc.
Publication of HUP0302665A2 publication Critical patent/HUP0302665A2/hu
Publication of HUP0302665A3 publication Critical patent/HUP0302665A3/hu
Publication of HU226857B1 publication Critical patent/HU226857B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya a (2) képletű, sejtburjánzás ellenes hatású N-(3-etinilfenil)-6,7-bisz(2-metoxi-etoxi)-4-kinazolinamin-hidroklorid sóB-vel jelölt kristályos módosulata, amelynek Röntgen sugárpordiffrakciós diagramján a jellemző csúcsok 2q-ban kifejezvekörülbelül a következők: 6,26, 12,48, 13,39, 16,96, 20,20, 21,10,22,98, 24,46, 25,14, 26,91. A találmány tárgya továbbá az N-(3-etinilfenil)-6,7-bisz(2-metoxietoxi)-4-kinazolin-amin-hidroklorid sóA-val jelölt kristályos módosulata, amely lényegében mentes Bmódosulattól. A találmány tárgya továbbá eljárás az N-(3-etinilfenil)-6,7-bisz (2-metoxietoxi)-4-kinazolinamin-hidroklorid só B-vel jelöltkristályos módosulatának előállítására, melynek során az N-(3-etinilfenil)-6,7-bisz(2-metoxietoxi)-4-kinazolinamin-hidrokloridotalkoholt tartalmazó oldószerből átkristályosítják. A találmánykiterjed a stabil módosulatokat tartalmazó gyógyszerkészítményekre is. Ó
HU0302665A 1999-11-11 2000-11-09 N-(3-etinilfenil)-6,7-bisz(2-metoxietoxi)-4-kinazolinamin-hidroklorid stabil polimorf módosulatát tartalmazó gyógyszerkészítmény HU226857B1 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16490799P 1999-11-11 1999-11-11
US19319100P 2000-03-30 2000-03-30
US20642000P 2000-05-23 2000-05-23
PCT/US2000/031009 WO2001034574A1 (en) 1999-11-11 2000-11-09 Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof

Publications (3)

Publication Number Publication Date
HUP0302665A2 true HUP0302665A2 (hu) 2003-12-29
HUP0302665A3 HUP0302665A3 (en) 2004-03-29
HU226857B1 HU226857B1 (hu) 2009-12-28

Family

ID=27389075

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302665A HU226857B1 (hu) 1999-11-11 2000-11-09 N-(3-etinilfenil)-6,7-bisz(2-metoxietoxi)-4-kinazolinamin-hidroklorid stabil polimorf módosulatát tartalmazó gyógyszerkészítmény

Country Status (38)

Country Link
US (1) US6900221B1 (hu)
EP (4) EP1233948B1 (hu)
JP (1) JP4689916B2 (hu)
KR (1) KR100769264B1 (hu)
CN (1) CN100351241C (hu)
AP (1) AP1434A (hu)
AR (1) AR035563A1 (hu)
AT (1) ATE420645T1 (hu)
AU (3) AU784243B2 (hu)
BG (1) BG65880B1 (hu)
BR (1) BR0015544A (hu)
CA (2) CA2389333C (hu)
CL (1) CL2010000616A1 (hu)
CY (1) CY1112671T1 (hu)
CZ (1) CZ303897B6 (hu)
DE (1) DE60041415D1 (hu)
DK (1) DK1233948T3 (hu)
EA (1) EA005318B1 (hu)
ES (1) ES2320408T3 (hu)
GE (1) GEP20053503B (hu)
HK (1) HK1049663B (hu)
HR (1) HRP20020388B1 (hu)
HU (1) HU226857B1 (hu)
IL (2) IL149222A0 (hu)
IS (1) IS2612B (hu)
MA (1) MA25570A1 (hu)
ME (2) ME00328B (hu)
MY (1) MY129348A (hu)
NO (1) NO327082B1 (hu)
NZ (1) NZ518406A (hu)
PL (1) PL223486B1 (hu)
PT (1) PT1233948E (hu)
RS (1) RS51198B (hu)
SI (1) SI1233948T1 (hu)
SK (1) SK286995B6 (hu)
TW (1) TWI249528B (hu)
UA (1) UA74803C2 (hu)
WO (1) WO2001034574A1 (hu)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
AU2004207720A1 (en) * 2003-01-31 2004-08-12 Teijin Pharma Limited Crystal of (23S)-1alpha-hydroxy-27-nor-25-methylenevitamin D3-26,23-lactone and process for producing the same
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP1633758B1 (en) * 2003-05-15 2011-11-23 Arqule, Inc. Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
CN100378101C (zh) 2003-06-10 2008-04-02 霍夫曼-拉罗奇有限公司 1.3.4-三氮杂-非那烯和1,3,4,6-四氮杂非那烯衍生物
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
AU2005249206A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an EGFR-inhibitor
KR100986945B1 (ko) * 2004-06-03 2010-10-12 에프. 호프만-라 로슈 아게 젬시타빈 및 ｅｇｆｒ-억제제로의 치료
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
CA2584368A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US7625911B2 (en) 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
DE602006016085D1 (de) 2005-03-16 2010-09-23 Genentech Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP3173084B1 (en) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
US7960545B2 (en) 2005-11-23 2011-06-14 Natco Pharma Limited Process for the prepartion of erlotinib
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
EA022613B1 (ru) 2006-06-09 2016-02-29 Юниверсити Корт Ов Де Юниверсити Ов Абердин Усиленное резонансом бурение: способ и устройство
WO2008012105A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
JP2010502743A (ja) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
SG174774A1 (en) * 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US7977347B2 (en) * 2006-09-11 2011-07-12 Curis, Inc. Quinazoline based EGFR inhibitors
ES2385613T3 (es) 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Método para tratar cánceres que portan mutaciones de EGFR
US8372856B2 (en) * 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
WO2008053270A2 (en) * 2006-10-31 2008-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an egfr antagonist for the treatment of glomerolonephritis
US20100260674A1 (en) * 2006-12-15 2010-10-14 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
WO2008076949A2 (en) * 2006-12-15 2008-06-26 Concert Pharmaceuticals Inc. Quinazoline derivatives and methods of treatment
US8349855B2 (en) 2007-02-21 2013-01-08 Natco Pharma Limited Polymorphs of erlotinib hydrochloride and method of preparation
JP5524041B2 (ja) * 2007-04-04 2014-06-18 シプラ・リミテッド エルロチニブおよびその薬学的に許容可能な塩の製造方法
KR20100024494A (ko) * 2007-06-22 2010-03-05 아르퀼 인코포레이티드 퀴나졸리논 화합물 및 이의 사용 방법
WO2009002538A2 (en) * 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
EP2162444B1 (en) 2007-07-11 2014-06-04 Hetero Drugs Limited An improved process for the preparation of erlotinib hydrochloride
EP2170062A4 (en) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
EP2213665A1 (en) 2007-08-17 2010-08-04 Hetero Drugs Limited Erlotinib hydrochloride
WO2009025875A1 (en) * 2007-08-23 2009-02-26 Plus Chemicals Sa Stable formulations of crystalline erlotinib hcl
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US8119616B2 (en) * 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2009035718A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
EP2217580B1 (en) * 2007-10-12 2011-12-21 ArQule, Inc. Substituted tetrazole compounds and uses thereof
NZ584695A (en) * 2007-10-19 2011-06-30 Pharma Mar Sa Improved antitumoral treatments using PM02734 and an EGFR tyrosine kinase inhibitor (erlotinib)
ES2642159T3 (es) * 2008-01-18 2017-11-15 Natco Pharma Limited Proceso para la preparación de derivados de 6,7-dialcoxi-quinazolina
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
CA2716851A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and egfr antagonists
CA2717117A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
JP2011516426A (ja) * 2008-03-28 2011-05-26 コンサート ファーマシューティカルズ インコーポレイテッド キナゾリン誘導体および治療方法
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
WO2010005924A1 (en) * 2008-07-07 2010-01-14 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
CN102317293A (zh) * 2008-12-05 2012-01-11 艾科尔公司 Raf抑制剂及其用途
EP2213281A1 (en) 2009-02-02 2010-08-04 Ratiopharm GmbH Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9050341B2 (en) * 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
JP2013510564A (ja) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
KR101208956B1 (ko) * 2010-07-15 2012-12-06 주식회사 셀트리온제약 엘로티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
AU2011298167B2 (en) 2010-07-23 2015-11-26 Generics [Uk] Limited Pure erlotinib
CN101914068A (zh) * 2010-08-14 2010-12-15 浙江华海药业股份有限公司 一种厄洛替尼碱的新晶型及其制备方法
CN101948441B (zh) * 2010-09-07 2012-07-25 江苏先声药物研究有限公司 一种Erlotinib盐酸盐A晶型的制备方法
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
JP2014503499A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく治療に適した被験体の事前選択
JP2014503500A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
KR20200003933A (ko) 2011-03-04 2020-01-10 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
US9295676B2 (en) 2011-03-17 2016-03-29 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of EGFR
CN103648500B (zh) 2011-03-17 2016-05-04 宾夕法尼亚大学理事会 双功能酶制钳型分子的方法和用途
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
SG194045A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
US20140121373A1 (en) 2011-05-03 2014-05-01 Cadila Healthcare Limited Process for preparing stable polymorphic form of erlotinib hydrochloride
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
RU2614254C2 (ru) 2011-08-31 2017-03-24 Дженентек, Инк. Диагностические маркеры
EP2761025A1 (en) 2011-09-30 2014-08-06 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013170182A1 (en) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
CN103420922B (zh) * 2012-05-18 2016-08-31 重庆华邦制药有限公司 一种工业化生产盐酸厄洛替尼b型晶的方法
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
WO2014118112A1 (en) 2013-01-29 2014-08-07 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
AU2014228166A1 (en) 2013-03-15 2015-09-24 Mirna Therapeutics, Inc. Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
CN104119284A (zh) * 2013-04-28 2014-10-29 广东东阳光药业有限公司 厄洛替尼新晶型及其制备方法
CN103435559B (zh) * 2013-07-03 2015-05-13 山东金城医药化工股份有限公司 盐酸厄洛替尼新晶型及其制备方法
CN103508962B (zh) * 2013-07-03 2016-04-13 山东金城医药化工股份有限公司 盐酸厄洛替尼b晶型的制备方法
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
CN103980207B (zh) * 2014-04-04 2016-03-09 亿腾药业（泰州）有限公司 一种盐酸厄洛替尼b型晶的合成方法
MX2016014531A (es) 2014-05-07 2017-05-01 Remedica Ltd Pureza polimorfica, monitoreo y composiciones asociadas.
KR101592258B1 (ko) 2014-06-20 2016-02-05 보령제약 주식회사 제제 및 이의 제조방법
WO2016082879A1 (en) * 2014-11-27 2016-06-02 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
CA2969830A1 (en) 2014-12-24 2016-06-30 Genentech, Inc. Therapeutic, diagnostic and prognostic methods for cancer of the bladder
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
RU2610337C1 (ru) * 2015-12-10 2017-02-09 Индивидуальный предприниматель Михайлов Олег Ростиславович Кристаллическая β-модификация N-(3-этинилфенил)-6,7-бис(2 метоксиэтокси)хиназолин-4-амин гидрохлорида, способ её получения и фармацевтическая композиция на её основе
JP2019059685A (ja) * 2017-09-26 2019-04-18 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
JP2021506974A (ja) 2017-12-18 2021-02-22 スターングリーン、インク． チロシンキナーゼ阻害剤として有用なピリミジン化合物
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800039A (en) 1970-10-21 1974-03-26 Mead Johnson & Co Antithrombogenic process employing substituted 6,7-dialkoxyquinazolines
US4139561A (en) 1978-02-27 1979-02-13 Gulf Research & Development Company Novel substituted amino-aromatic acetylenes and their method of preparation
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4219679A (en) 1978-11-06 1980-08-26 Gulf Research & Development Company Selective hydrogenation of nitro groups on nitroaromatic acetylenes using an unsupported cobalt polysulfide catalyst
US4216341A (en) 1978-11-06 1980-08-05 Gulf Research & Development Company Selective hydrogenation of certain nitroaromatic hydroxy substituted acetylenes over a heterogeneous RuS2 catalyst
US4255313A (en) 1979-04-20 1981-03-10 Gulf Oil Corporation Novel end-capped polyimide oligomers
US4281127A (en) 1979-07-09 1981-07-28 Hoffmann-La Roche Inc. Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
US4305751A (en) 1980-04-16 1981-12-15 Gulf Oil Corporation M-Alkynylanilides and use as herbicides
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
JPS6448048A (en) 1987-08-19 1989-02-22 Oki Electric Ind Co Ltd Organic nonlinear optical material and nonlinear optical element
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US6004979A (en) 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5214144A (en) 1991-10-07 1993-05-25 Dowelanco Process for the preparation of 4-haloquinazolines
US5256781A (en) 1991-10-24 1993-10-26 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
US5639881A (en) 1991-11-08 1997-06-17 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis and elucidation of pyrimido (4,5-Q) quinazoline derivatives
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
JP2994165B2 (ja) 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
JPH06205969A (ja) 1992-10-13 1994-07-26 Tajima Inc 板状体加熱処理用仕切板とそれを用いた加熱方法
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
KR0144833B1 (ko) 1992-12-28 1998-07-15 김태훈 신규의 퀴나졸린 유도체 및 그의 제조방법
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JP2646995B2 (ja) 1993-01-28 1997-08-27 武田薬品工業株式会社 キノリンまたはキナゾリン誘導体およびそれらを含んでなる医薬
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
JPH07126255A (ja) 1993-09-10 1995-05-16 Eisai Co Ltd キナゾリン系化合物
JP3265083B2 (ja) 1993-09-30 2002-03-11 味の素ファルマ株式会社 ２−［２−（置換アミノ）ベンジルチオ］−５，６，７，８−テトラヒドロ−４（３ｈ）−キナゾリノン誘導体
JP3117371B2 (ja) 1993-11-05 2000-12-11 三井化学株式会社 フロベンゾピラン誘導体及びそれらを有効成分とする除草剤
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1996003034A1 (en) * 1994-07-27 1996-02-08 Massachusetts Institute Of Technology Method for retroviral vector insertion in fish
JPH09165385A (ja) 1994-08-26 1997-06-24 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (hu) 1994-11-12 1997-12-01 Zeneca Ltd
JPH08151377A (ja) 1994-11-25 1996-06-11 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
ATE241639T1 (de) 1995-02-14 2003-06-15 Human Genome Sciences Inc Keratinozyten-wachstumsfaktor 2
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
AU704544B2 (en) 1995-03-14 1999-04-29 Novartis Ag Trisubstituted phenyl derivatives
EP3103799B1 (en) * 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
EP0821671B1 (en) 1995-04-20 2000-12-27 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
EP0776895B1 (en) 1995-11-20 1998-10-14 Eli Lilly And Company Protein kinase C inhibitor
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
IL126351A0 (en) 1996-04-12 1999-05-09 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
DK0912559T3 (da) 1996-07-13 2003-03-10 Glaxo Group Ltd Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6207669B1 (en) 1996-07-13 2001-03-27 Glaxo Wellcome Inc. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
JPH1036326A (ja) 1996-07-18 1998-02-10 Fuji Photo Film Co Ltd ３−エチニルアニリン化合物の酸付加塩及び３−エチニルアニリン化合物の精製方法
TR199900066T2 (xx) 1996-07-18 1999-04-21 Pfizer Inc. Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
JPH1036325A (ja) 1996-07-18 1998-02-10 Fuji Photo Film Co Ltd アミノフェニルアセチレン化合物の製造方法
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
US6004967A (en) 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
BR9807815A (pt) 1997-02-03 2000-03-08 Pfizer Prod Inc Derivados de ácido arilsulfonilamino-hidroxâmico
WO1998034915A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
HUP0000657A3 (en) 1997-02-11 2000-10-30 Pfizer N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them
EP0984930B1 (en) 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
JP2002501532A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
CN1234880A (zh) * 1997-07-28 1999-11-10 株式会社资生堂 含有合成云母的投影屏
WO1999010349A1 (en) 1997-08-22 1999-03-04 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
EP1028964A1 (en) 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
ATE295839T1 (de) * 1998-04-29 2005-06-15 Osi Pharm Inc N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethox )-4-chinazolinamin-mesylat-anhydrat und -monohydrat
WO1999060023A1 (en) 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
AU759226B2 (en) 1998-05-29 2003-04-10 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
NZ527718A (en) 1998-11-19 2004-11-26 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
YU13200A (sh) * 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
CA2403721C (en) 2000-03-20 2009-06-09 Pfizer Products, Inc. Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
US10181126B2 (en) 2012-03-13 2019-01-15 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
CL2010000616A1 (es) 2011-04-01
IS6359A (is) 2002-04-24
AU784243B2 (en) 2006-02-23
HK1049663A1 (en) 2003-05-23
EP3100730A1 (en) 2016-12-07
PT1233948E (pt) 2009-04-16
HUP0302665A3 (en) 2004-03-29
HK1049663B (zh) 2009-06-12
SK286995B6 (sk) 2009-09-07
CA2632556C (en) 2012-01-03
AU1762101A (en) 2001-06-06
NO20021910D0 (no) 2002-04-23
UA74803C2 (uk) 2006-02-15
EP1233948A1 (en) 2002-08-28
EP1233948A4 (en) 2004-01-28
KR20020063889A (ko) 2002-08-05
SI1233948T1 (sl) 2009-06-30
PL355235A1 (en) 2004-04-05
NO327082B1 (no) 2009-04-20
IL149222A0 (en) 2002-11-10
EP2168581A2 (en) 2010-03-31
CA2632556A1 (en) 2001-05-17
EA200200546A1 (ru) 2002-12-26
AU2009251148A1 (en) 2010-01-21
KR100769264B1 (ko) 2007-10-23
CN100351241C (zh) 2007-11-28
AU2006201815A1 (en) 2006-05-25
AP1434A (en) 2005-06-20
NZ518406A (en) 2004-01-30
HRP20020388B1 (hr) 2013-02-28
EP2168581A3 (en) 2010-07-21
AR035563A1 (es) 2004-06-16
AP2002002542A0 (en) 2002-06-30
MA25570A1 (fr) 2002-10-01
EP2292233A3 (en) 2011-07-27
EP1233948B1 (en) 2009-01-14
BG106761A (bg) 2003-01-31
CN1414954A (zh) 2003-04-30
DE60041415D1 (de) 2009-03-05
CZ20022019A3 (cs) 2003-05-14
EP2292233A2 (en) 2011-03-09
HU226857B1 (hu) 2009-12-28
ES2320408T3 (es) 2009-05-22
ATE420645T1 (de) 2009-01-15
US6900221B1 (en) 2005-05-31
CZ303897B6 (cs) 2013-06-12
CA2389333C (en) 2008-09-02
BR0015544A (pt) 2002-07-23
DK1233948T3 (da) 2009-04-27
MY129348A (en) 2007-03-30
AU2006201815B2 (en) 2009-10-01
TWI249528B (en) 2006-02-21
YU34202A (sh) 2005-06-10
GEP20053503B (en) 2005-05-10
ME00328B (me) 2011-05-10
SK5812002A3 (en) 2002-09-10
JP4689916B2 (ja) 2011-06-01
IL177827A (en) 2014-01-30
HRP20020388A2 (en) 2004-06-30
PL223486B1 (pl) 2016-10-31
CY1112671T1 (el) 2016-02-10
IS2612B (is) 2010-04-15
EA005318B1 (ru) 2004-12-30
IL177827A0 (en) 2006-12-31
EP2168581A9 (en) 2011-07-20
JP2003523949A (ja) 2003-08-12
MEP36308A (en) 2011-02-10
NO20021910L (no) 2002-07-01
BG65880B1 (bg) 2010-04-30
CA2389333A1 (en) 2001-05-17
RS51198B (sr) 2010-12-31
WO2001034574A1 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
HUP0302665A2 (hu) N-(3-etinilfenil)-6,7-bisz(2-metoxietoxi)-4-kinazolinamin-hidroklorid stabil módosulata, és eljárás előállítására, ezt tartalmazó gyógyszerkészítmények és alkalmazása
HUP0400704A2 (hu) Heterociklusos éterrel szubsztituált imidazokinolinok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
Bacelar et al. Synthesis and in vitro evaluation of substituted pyrimido [5, 4-d] pyrimidines as a novel class of Antimycobacterium tuberculosis agents
HUP0303128A2 (hu) O-dezmetil-venlafaxin új szukcinátsója, eljárás az előállításukra, alkalmazása és ezt tartalmazó gyógyszerkészítmény
NO20051010L (no) Triazolderivater som transformerende vekst faktor (TGF) inhibitorer
ES8800899A1 (es) Procedimiento para preparar derivados de amidoinzol y amidoinzadol
ZA200401461B (en) Heterocyclic compound based on n6 substituted adenine methods of their preparation their use for preparation of drugs cosmetic preparations and growth regulators pharmaceutical prepartion cosmetic preparations and growth regulators containing these compou
HUP0203521A2 (hu) Kristályos 4-karboxi-amino-2-etil-1,2,3,4-tetrahidro-kinolin CEPT inhibitor, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
RU93004926A (ru) Производные хинолина и хиназолина, способ их получения и фармацевтическая композиция
HUP0301458A2 (hu) Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása
NZ516506A (en) Interleukin-5 inhibiting 6-azauracil derivatives
CY1108590T1 (el) Τυποποιημενα παρασκευασματα λακτονης και μεθοδος χρησης
HUP0402602A2 (hu) Eljárás echinokandin-származékok előállítására, ezek alkalmazása, ezeket tartalmazó gyógyszerkészítmények és intermedierek
HUP0105308A2 (hu) Eletriptán-hidrobromid-monohidrát, eljárás az előállítására és a vegyületet tartalmazó gyógyszerkészítmények
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
HUP0100019A2 (hu) A cipamfillin új polimorf formái, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0401443A2 (hu) LH- és FSH-agonista aktivitású glicinhelyettesített tieno[2,3-d]pirimidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0303181A2 (hu) 4-Foszfodiészteráz típusú inhibitorok alkalmazása miokardiális betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
HUP0402658A2 (hu) Variolinszármazékok és ezeket tartalmazó daganatellenes gyógyászati készítmények
HUP0204009A2 (hu) 1. típusú nátrium-hidrogén csere (NHE-1) gátló kristályok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE69907671D1 (en) Hydroxyphenylsulfanylbenzoesäure- und -arylessigsäure-derivate
NO984699L (no) Fenyletanolamino-tetralinkarboks-amid-derivater
FR2781482B1 (fr) Nouveaux derives de 8h-thieno-[2,3-b]pyrrolizine-8-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: OSI PHARMACEUTICALS, LLC, US

Free format text: FORMER OWNER(S): OSI PHARMACEUTICALS, INC., US